Effect of dolutegravir in combination with Nucleoside Reverse Transcriptase Inhibitors (NRTIs) on people living with HIV who have pre-existing NRTI mutations

• Published in: International journal of antimicrobial agents Vol. 51; no. 5; pp. 733 - 738
• Main Authors: Sörstedt, Erik, Carlander, Christina, Flamholc, Leo, Hejdeman, Bo, Svedhem, Veronica, Sönnerborg, Anders, Gisslén, Magnus, Yilmaz, Aylin
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.05.2018
• Subjects: Antiretroviral therapy; antiretroviral-naive adults; Dolutegravir; double-blind; drug-resistance; elvitegravir; HIV-1; Infectious Medicine; Infektionsmedicin; monotherapy; non-inferiority; NRTI; Nucleoside reverse transcriptase inhibitor; once-daily dolutegravir; raltegravir; Resistance; treatment-experienced subjects; twice-daily; type-1 infection; HIV-1; Resistance; Nucleoside reverse transcriptase inhibitor; NRTI; Antiretroviral therapy; Dolutegravir

•First comparison between PI/r and dolutegravir in PLWH with baseline NRTI resistance.•A real-life setting involving intermediate- to high-level baseline NRTI resistance.•No new mutations were found among participants with treatment failure.•Dolutegravir is equally as efficient as traditional PI/r....